Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | ABCC9 | O60706 | 2/20 | 0.31 |
| ▸ | ABCC8 | Q09428 | 2/20 | 0.31 |
| ▸ | KCNJ11 | Q14654 | 2/20 | 0.31 |
| ▸ | KCNJ8 | Q15842 | 2/20 | 0.31 |
| ▸ | PTPRC | P08575 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | MITF | O75030 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4357785 | 0.89 | ALOX15 (0.34) | TNK2ALOX15PTPRC | |
| SCHEMBL4362590 | 0.88 | CYP1A2 (0.36) | ALDH1A1HPGDTNK2ALOX15ABCC9 | |
| SCHEMBL4365532 | 0.85 | MEN1 (0.33) | RAB9ALMNA | |
| SCHEMBL4356084 | 0.82 | TNK2 (0.30) | TNK2 | |
| SCHEMBL4357435 | 0.81 | TNK2 (0.31) | TNK2 | |
| SCHEMBL1129530 | 0.78 | MAPT (0.33) | POLBTNK2 | |
| SCHEMBL4354030 | 0.77 | MAPK13 (0.33) | TNK2ALOX15 | |
| SCHEMBL4365479 | 0.77 | TNK2 (0.34) | POLBALDH1A1HPGDSMN1; SMN2TNK2 | |
| SCHEMBL4362655 | 0.77 | TNK2 (0.45) | POLBALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL2462686 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8481733-B2 | Substituted imidazopyr- and imidazotri-azines | OSI Pharmaceuticals, LLC (US) | 2013-07-09 | — | — | US | disclosed |
| US-20090286768-A1 | SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES | OSI PHARMACEUTICALS, INC. (US) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286768-A1 | SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES | ABL1, TPMT, CYP2C19 | POLB 3878/4885ALDH1A1 292/4885HPGD 1283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.